DV
Dividend Vision

KYMR — Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. (KYMR)

Total return is 252.9% over the past 6 years, 104.6 points ahead of SPY at 148.3%. Its deepest 1-year drawdown was 27.7%.

Kymera Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics that degrade disease-causing proteins using the body's natural protein degradation system. The company's pipeline includes KT-621, an oral STAT6 degrader in Phase 2b trials for inflammatory conditions including atopic dermatitis and asthma; KT-579, an oral IRF5 degrader in Phase 1 development for autoimmune diseases; KT-485, an IRAK4 program in Phase II for immunology-inflammation diseases; and CDK2 candidates with oncology potential. As a clinical-stage biopharmaceutical company with no approved products, Kymera does not currently distribute dividends and appeals to investors focused on long-term growth in the biotech sector.

KYMR key facts

Asset type
Stock
Asset class
Equity
Inception date
08/21/2020
Distribution frequency
None
Last close
$117.39
Market cap
$9,411,912,704
Average volume
468600.0
Beta
1.954
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.26